In contrast, the NLRP3 inflammasome seems to have antitumor activity in multiple myeloma (MM) [53] and chronic lymphocytic leukemia (CLL) [54], in which it is expressed at lower levels in cancer patients than in healthy controls. The gene discussed is NLRP3; the disease is B-cell chronic lymphocytic leukemia.